Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shenzhen Hepalink Forms Anti-infective mAb JV with Aridis Pharma

publication date: Feb 27, 2018

Shenzhen Hepalink formed a JV with Aridis Pharma, a San Francisco area biopharma, to gain China approval for Aridis' fully human monoclonal antibody therapies. The JV will be backed by a "significant," though undisclosed, capital commitment. It will develop two of Aridis' mAb clinical candidates, AR-301 and AR-101, for difficult-to-treat infections. To discover drugs, Aridis identifies subsets of patients who are not affected by a particular infectious disease, isolating and immortalizing the group's protective mAbs. Aridis uses them to produce therapeutic antibodies. More details....

Stock Symbol: (SHZ: 2399)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.